Phio Pharmaceuticals (PHIO) EBT Margin (2012 - 2019)
Phio Pharmaceuticals' (PHIO) quarterly EBT Margin came in at 13171.43% in Q1 2019, down 343665.0% YoY from N/an in Q1 2018, and down 402.86% on a QoQ basis from 2619.3% in Q3 2018.
Phio Pharmaceuticals (PHIO) EBT Margin (2012 - 2019) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 8 years of EBT Margin data on file, last reported at 13171.43% in Q1 2019.
- Quarterly EBT Margin fell 343665.0% year-over-year to 13171.43% in Q1 2019, while the trailing twelve-month figure through Dec 2019 was 46190.48% (down 4085714.0% YoY) and the FY2019 annual result came in at 42419.05%, down 3708571.0% from the prior year.
- EBT Margin slipped to 13171.43% in Q1 2019, from 2619.3% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2619.3% in Q3 2018 to a low of 24577.78% in Q2 2016.
- A 5-year average of 12212.78% and a median of 11453.11% in 2018 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2015 — EBT Margin soared 916001 bps — and 2016, when it plunged 1364529 bps.
- Tracing PHIO's EBT Margin over 5 years: stood at 8664.71% in 2015, then plunged by 184 bps to 24577.78% in 2016, then surged by 46 bps to 13346.67% in 2017, then jumped by 80 bps to 2619.3% in 2018, then tumbled by 403 bps to 13171.43% in 2019.
- The last three EBT Margin figures came in at 13171.43% (Q1 2019), 2619.3% (Q3 2018), and 3277.59% (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -13,171.43% |
| Sep 30, 2018 | -2,619.30% |
| Jun 30, 2018 | -3,277.59% |
| Mar 31, 2018 | -9,734.78% |
| Dec 31, 2017 | -13,346.67% |
| Jun 30, 2016 | -24,577.78% |
| Mar 31, 2016 | -22,310.00% |
| Mar 31, 2015 | -8,664.71% |
| Dec 31, 2014 | -144,578.57% |
| Sep 30, 2014 | -13,806.25% |
| Jun 30, 2014 | -23,341.67% |
| Mar 31, 2014 | -17,824.72% |
| Dec 31, 2013 | -9,251.72% |
| Sep 30, 2013 | -2,251.09% |
| Jun 30, 2013 | -873.33% |
| Mar 31, 2013 | -49,767.92% |
| Dec 31, 2012 | -4,282.50% |
| Sep 30, 2012 | -4,709.75% |